|
|
Blood, 15 October 2006, Vol. 108, No. 8, pp. 2720-2725.
Prepublished online as a Blood First Edition Paper on April 11, 2006; DOI 10.1182/blood-2006-01-009480.
 Previous Article | Next Article 
Submitted January 26, 2006
Accepted March 28, 2006
FcGRIIIa gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma
Dong Hwan Kim*, Hee Du Jung, Jong Gwang Kim, Je-Jung Lee, Deok-Hwan Yang, Yeon Hee Park, Young Rok Do, Ho Jin Shin, Min Kyoung Kim, Myung Soo Hyun, and Sang Kyun Sohn
Samsung Medical Center, Sungkyunkwan University
Kyungpook National University Hospital
Chonnam National University Hwasun Hospital
Keimyung University, Dongsan Medical Center
Pusan National University Hospital
Yeungnam University, Yeungnam Medical Center
* Corresponding author; email: kiim{at}knu.ac.kr.
The precise mechanism of rituximab (R) plus
CHOP (R-CHOP) therapy in diffuse large B-cell lymphoma
(DLBCL) is not fully elucidated: Besides overcoming bcl-
2 mediated chemoresistance, antibody-dependent cellular
cytotoxicity (ADCC), which is activated by effector
cells via IgG fragment C receptors (FcR), was also
proposed as a mechanism of Rituximab. The current study
evaluated the impact of FcR polymorphism on the response
to R-CHOP therapy for DLBCL with the basis that FcR
polymorphism can affect R’ s affinity for ADCC effector
cells. The FcyRIIIa and FcyRIIIa
gene polymorphisms were determined in DLBCL patients
receiving R-CHOP (n=113) comparing to CHOP therapy
(n=85). The FcyRIIIa valine (V) allele was
significantly correlated with higher complete response
rate to R-CHOP compared to phenylalalnine (F) allele
(88% in V/V versus 79% in V/F versus 50% in F/F,
p=0.002), while no difference was found between FcyRIIIa
polymorphism. In addition, V/V allele was associated
with faster achievement of response than other alleles.
The impact of FcyRIIIa gene polymorphism on response
rate was not noted in CHOP group. In terms of overall or
event-free survival, no difference was found according
to FcyRIIIa or FcyRIIIa alleles. The FcyRIIIa
SNP is predictive of response to R-CHOP, but does not
correlate with survival in DLBCL patients.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. Shibata-Koyama, S. Iida, A. Okazaki, K. Mori, K. Kitajima-Miyama, S. Saitou, S. Kakita, Y. Kanda, K. Shitara, K. Kato, et al.
The N-linked oligosaccharide at Fc{gamma}RIIIa Asn-45: an inhibitory element for high Fc{gamma}RIIIa binding affinity to IgG glycoforms lacking core fucosylation
Glycobiology,
February 1, 2009;
19(2):
126 - 134.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Lejeune, G. Thibault, D. Ternant, G. Cartron, H. Watier, and M. Ohresser
Evidence for Linkage Disequilibrium Between Fc{gamma}RIIIa-V158F and Fc{gamma}RIIa-H131R Polymorphisms in White Patients, and for an Fc{gamma}RIIIa-Restricted Influence on the Response to Therapeutic Antibodies
J. Clin. Oncol.,
November 20, 2008;
26(33):
5489 - 5491.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. D. Cheson and J. P. Leonard
Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma
N. Engl. J. Med.,
August 7, 2008;
359(6):
613 - 626.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. O. Richards, S. Karki, G. A. Lazar, H. Chen, W. Dang, and J. R. Desjarlais
Optimization of antibody binding to Fc{gamma}RIIa enhances macrophage phagocytosis of tumor cells
Mol. Cancer Ther.,
August 1, 2008;
7(8):
2517 - 2527.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. M. Pennell, T. Bhanji, L. Zhang, A. Seth, C. A. Sawka, and N. L. Berinstein
Lack of prognostic value of FCGR3A-V158F polymorphism in non-Hodgkin's lymphoma
Haematologica,
August 1, 2008;
93(8):
1265 - 1267.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Natsume, M. In, H. Takamura, T. Nakagawa, Y. Shimizu, K. Kitajima, M. Wakitani, S. Ohta, M. Satoh, K. Shitara, et al.
Engineered Antibodies of IgG1/IgG3 Mixed Isotype with Enhanced Cytotoxic Activities
Cancer Res.,
May 15, 2008;
68(10):
3863 - 3872.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Musolino, N. Naldi, B. Bortesi, D. Pezzuolo, M. Capelletti, G. Missale, D. Laccabue, A. Zerbini, R. Camisa, G. Bisagni, et al.
Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu-Positive Metastatic Breast Cancer
J. Clin. Oncol.,
April 10, 2008;
26(11):
1789 - 1796.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. W. Hauswirth and U. Jager
Impact of cytogenetic and molecular prognostic markers on the clinical management of chronic lymphocytic leukemia
Haematologica,
January 1, 2008;
93(1):
14 - 19.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Taylor, D. Hershman, N. Shah, N. Suciu-Foca, D. P. Petrylak, R. Taub, L. Vahdat, B. Cheng, M. Pegram, K. L. Knutson, et al.
Augmented HER-2 Specific Immunity during Treatment with Trastuzumab and Chemotherapy
Clin. Cancer Res.,
September 1, 2007;
13(17):
5133 - 5143.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Carlotti, G. A. Palumbo, E. Oldani, D. Tibullo, S. Salmoiraghi, A. Rossi, J. Golay, A. Pulsoni, R. Foa, and A. Rambaldi
Fc{gamma}RIIIA and Fc{gamma}RIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab
Haematologica,
August 1, 2007;
92(8):
1127 - 1130.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Baatar, P. Olkhanud, D. Newton, K. Sumitomo, and A. Biragyn
CCR4-Expressing T Cell Tumors Can Be Specifically Controlled via Delivery of Toxins to Chemokine Receptors
J. Immunol.,
August 1, 2007;
179(3):
1996 - 2004.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Mitrovic, I. Aurer, I. Radman, R. Ajdukovic, J. Sertic, and B. Labar
FC{gamma}RIIIA and FC{gamma}RIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma
Haematologica,
July 1, 2007;
92(7):
998 - 999.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
